Damora Therapeutics, Inc. Common Stock (DMRA) – What Are Analysts Saying About This Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has been assigned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $46.50.

A number of analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Wall Street Zen raised shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research note on Sunday, October 11th. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st.

Insiders Place Their Bets

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett purchased 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction that occurred on Friday, September 25th. The stock was bought at an average price of $20.23 per share, with a total value of $252,875.00. Following the acquisition, the chief executive officer owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.40% of the company’s stock.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors have recently bought and sold shares of the business. Arizona State Retirement System purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $260,000. Squarepoint Ops LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $303,000. Seven Fleet Capital Management LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $7,398,000. Finally, Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $42,146,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Trading Up 4.5%

Shares of NASDAQ:DMRA opened at $19.27 on Thursday. Damora Therapeutics, Inc. Common Stock has a 12-month low of $4.95 and a 12-month high of $38.33. The business has a 50 day moving average of $25.24 and a two-hundred day moving average of $25.68. The company has a market capitalization of $1.19 billion, a PE ratio of -5.72 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.06. Equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.